Pinned Tweet
GSK paid $110 million in cash for a molecule that has never been given to a human being. Two days earlier Roche paid $75 million for another one. Both sellers are Chinese, and neither asset has a clinical trial behind it.
On September 3 HUTCHMED licensed HMPL-A830 to GSK. It is an anti-EGFR antibody carrying a selective KRAS small-molecule inhibitor as its payload, which the company calls a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. GSK takes worldwide rights outside mainland China, Hong Kong, Macau and Taiwan, for $110 million upfront and up to $1.185 billion in milestones, plus tiered royalties. HUTCHMED runs the global Phase 1 itself, starting in the second half of this year under NCT07718581. GSK also took a right of first negotiation on one earlier-stage conjugate from the same platform.
I owe a correction on this. On Thursday I closed a post about KRAS G12D by calling Tyligand's preclinical EGFR-KRAS conjugate the one thing in its pipeline that nobody ahead of it was running. GSK had paid $110 million for that architecture seven days before I wrote it. The sentence was narrowly true about the KRAS G12D companies and wrong about the field.
The architecture deserves the attention. An antibody-drug conjugate delivers a cytotoxin and kills whatever it reaches. This delivers a signalling inhibitor instead, so the antibody does two jobs at once: it blocks EGFR, and it concentrates a KRAS drug inside cells that display the receptor. Every KRAS inhibitor outside G12C has run into the same wall, which is that the concentration the tumour needs is more than the rest of the patient will tolerate. HUTCHMED frames the gap as non-G12C disease and has not said which mutations the payload covers. That is the number to ask for before the Phase 1 reads out.
Two days before that, Roche licensed SIM0660 from Simcere Zaiming, the oncology arm of Simcere Pharmaceutical. It is a trispecific antibody that grips CD79a and CD19 on B cells and CD3 on T cells, aimed at patients who have already failed CD19 or CD20 therapy, and at B-cell autoimmune disease. Seventy-five million dollars upfront, up to $1.53 billion, global rights. Also preclinical.
So $185 million of Western cash went into two Chinese molecules in one week, neither of which has a human dose behind it. Preclinical assets used to be the part of a Chinese pipeline a buyer got thrown in with the package. They are now the thing being bought, which means the diligence sits on the platform and the chemistry rather than on a response rate, and the buyer is paying for a thesis it cannot yet check.
$HCM $GSK $2096 HK $RHHBY $XBI $IBB
✨ Made with AI
Impact Therapeutics' PARP inhibitor senaparib (Sepalna) now has EU approval, per its HKEX notice today.
The label: maintenance for adults with advanced (FIGO III–IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy. CHMP backed it on 17 Sep. The basis is FLAMES, a China Phase 3 (Nature Medicine, 2024): 404 patients, median PFS not reached vs 13.6 months on placebo, HR 0.43 (0.32–0.58), with similar benefit with and without BRCA mutations.
Why it matters: Impact calls it the first China-originated PARP inhibitor approved in the EU for all-comers first-line maintenance. It enters a setting held by AstraZeneca's Lynparza and GSK's Zejula. Triton-backed Pharmanovia holds Europe, MENA and ANZ rights: up to EUR 423.5M in upfront and milestones, plus royalties up to the mid-twenties percent.
$7630 HK $AZN $GSK $XBI $IBB
✨ Made with AI
🤖 Made with AI
32
Hengrui's weekly GLP-1/GIP shot ribupatide is now peer-reviewed: 17.7% mean weight loss at 48 weeks on the top dose (16.3 points over placebo), in JAMA (15 Nov).
GEMINI-1 is a Phase 3 at 55 sites in China in 567 adults with obesity or overweight and without diabetes. Treatment-policy weight change: 2 mg −10.7%, 4 mg −16.4%, 6 mg −17.7%, placebo −1.4%. On 6 mg, 44.4% lost at least 20%. GI side effects hit 63.1% on 6 mg vs 23.1% on placebo; 1.4% stopped for adverse events. Topline came out in 2025; the paper adds confidence intervals, responder tiers and the safety tables.
Why it matters: Lilly's tirzepatide 15 mg posted −17.5% at 52 weeks in its own China Phase 3 (SURMOUNT-CN, JAMA 2024). Different trials, similar range. Kailera holds the rights outside Greater China as KAI-9531; Hengrui owned 8.9% of Kailera at 30 June.
$600276 SH $1276 HK $KLRA $LLY $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
134
J&J is paying $2.2B upfront for an eye drug that Innovent discovered.
On 16 Nov J&J agreed to buy Ollin Biosciences for $2.2B upfront plus up to about $1.125B in milestones. Blackstone will pay J&J $750M over several years to fund the Phase 3. The asset is OLN324, a VEGF/Ang2 bispecific in a minibody format, in global Phase 3 for wet AMD and diabetic macular edema.
J&J's release does not name the originator. Innovent's HKEX notice the same day does: OLN324 is its IBI324, developed by Innovent and licensed out, and Innovent calls Ollin its partner. The licence terms have not been disclosed, so what Innovent collects from the sale is unknown.
The drug to beat is Roche's Vabysmo, the approved VEGF/Ang2 bispecific. Ollin ran a Phase 1b head-to-head against it, JADE.
What to watch: whether Innovent discloses its proceeds, or any China rights it keeps, before the deal closes (expected by year-end).
$1801 HK $JNJ $RHHBY $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
1
149
Each week, the five signals that matter most go to the BioSignal newsletter, with prompts for your AI agent. Free:
biosignal.beehiiv.com/?utm_s…
✨ Made with AI
🤖 Made with AI
39
Europe's regulator has backed the Chinese PD-1 the FDA rejected in 2022, on the same trial.
Innovent said on 15 Nov the EMA's CHMP recommends sintilimab (Zybrivo) with pemetrexed and platinum for first-line non-squamous NSCLC without EGFR or ALK alterations. The data: ORIENT-11, a Phase 3 run in China, n=397. Median PFS 8.9 vs 5.0 months; median OS 24.2 vs 16.8 months. EC decision expected in the coming months.
In March 2022 the FDA sent Lilly's US filing on ORIENT-11 a CRL, recommending a multiregional trial against standard of care with an OS endpoint.
Europe's regulator has now backed China-only ORIENT-11 data that the FDA would not.
$1801 HK $LLY $XBI $IBB
✨ Made with AI
🤖 Made with AI
136
JW Therapeutics' CAR-T relma-cel (Carteyva) goes on China's state reimbursement list at RMB 288,600 per infusion.
Per JW's HKEX announcement on 15 Nov, eligible patients in its three lymphoma indications get basic medical insurance reimbursement from 1 Jan 2027. NHSA's notice did not name it; it cited lymphoma CAR-Ts "originally priced above RMB 1 million". At about $40,000, it is roughly a tenth of US list prices for CD19 CAR-Ts.
Why it matters: the price is now public, so the volume math is too. JW shares swung from up 12% to down about 7% today.
$2126 HK $XBI $IBB
✨ Made with AI
🤖 Made with AI
150
JUST IN: GenFleet has dosed the first overseas patient, at Monash Health in Australia, in a Phase Ib/II of GFH276, its oral pan-RAS(ON) inhibitor (HKEX, 16 Nov). China dosing began in Q3.
The Phase II part tests it first line in pancreatic cancer, with cetuximab, with nab-paclitaxel/gemcitabine, and with mFOLFIRINOX.
The data behind it, Phase Ia at ESMO 2026, company-reported: ORR 41.1% in 61 evaluable pancreatic cancer patients, 72.6% of them third line or later. No dose-limiting toxicities at 40 to 160 mg once daily.
Why it matters: Revolution Medicines' daraxonrasib, FDA-approved in August for previously treated metastatic pancreatic cancer, sets the bar, and the next fight is first line.
$2595 HK $RVMD $XBI $IBB
✨ Made with AI
🤖 Made with AI
187
The FDA has turned down ivonescimab. Akeso fell nearly 32% in Hong Kong this morning.
Summit said on 15 Nov the FDA issued a CRL for ivonescimab plus chemo in EGFR-mutant non-squamous NSCLC after an EGFR TKI, filed on the HARMONi Phase 3. The FDA's reason: no statistically significant overall survival gain. PFS HR was 0.52. The prespecified OS analysis gave HR 0.79 (p=0.057); in Western patients at that cutoff, 0.98. Longer follow-up looked better (HR 0.76), but Summit calls it post hoc.
China approved the drug in this same setting in May 2024.
The read-through: the FDA wants a statistically significant OS gain in this setting, and that is the bar to watch for the PD-1xVEGF bispecifics that came out of China, including BMS/BioNTech's and Pfizer/3SBio's. Next test: HARMONi-3 squamous, where PFS events are expected this quarter, with an early OS interim alongside.
$SMMT $9926 HK $BMY $BNTX $PFE $1530 HK $XBI $IBB
✨ Made with AI
🤖 Made with AI
Each week, the five signals that matter most go to the BioSignal newsletter, with prompts for your AI agent. Free:
biosignal.beehiiv.com/?utm_s…
✨ Made with AI
🤖 Made with AI
33
This week's BioSignal newsletter is out: five signals, each with a prompt for your AI agent.
Allist has China and US clearance to test AST1001, an EGFR x c-MET ADC, after AstraZeneca discontinued its own EGFR x c-MET ADC trial.
Qyuns licensed a second TL1A bispecific to Caldera: $30M upfront and up to $750M in milestones.
Innovent's tafolecimab cut LDL-C 65.19% on its own at week 12 (company-reported), but China's new NRDL pays for it only alongside a statin.
JW Therapeutics is selling four liver-cancer T-cell programmes back to Eureka for $10M upfront.
Boan has China clearance to test BA2201, a TL1A x IL-23 bispecific, in ulcerative colitis.
Link in the reply.
$688578 SH $2509 HK $1801 HK $2126 HK $6955 HK $AZN $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
4
329
China has approved Evopoint's funobactam, a new β-lactamase inhibitor given with imipenem-cilastatin, for hospital-acquired and ventilator-associated bacterial pneumonia (company notice, 12 Nov).
The Phase 3 behind it, published in Lancet Infectious Diseases on 4 Nov: n=450, double-blind, against Merck's imipenem-relebactam (Recarbrio). 14-day all-cause mortality 3.0% (9/299) vs 2.7% (4/150), inside a 10% non-inferiority margin. 58 of the 62 sites were in China.
Why it matters: a China-discovered antibiotic now has a published head-to-head Phase 3 against a Merck-branded drug, a first piece of the package an ex-China partner would look for.
$688837 SH $MRK $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
205
Three Chinese licensors took part of their upfront in Windward Bio stock. After one day of trading, those shares were worth about three times what the deals valued them at.
Windward priced its Nasdaq IPO at $17 on 12 Nov and closed its first day, 13 Nov, at $28.50, up 68%. Sanofi bought $50M in a concurrent placement. Both of Windward's drugs come from China.
WIN378, a long-acting TSLP antibody from Kelun-Biotech and Harbour BioMed: $40M upfront, $20M of it in equity, 2,126,532 shares. At $28.50, about $61M.
WIN027, a TSLP x IL-13 bispecific from Qyuns: $30M upfront, $15M in equity, 1,594,898 shares held by its affiliate Linkbio. About $45M at the close.
These are paper gains. Qyuns also holds stock in Caldera, the US company carrying its TL1A bispecifics.
What I'm watching: WIN378's Phase 2 week-24 results in asthma, due 1H 2027.
$WWB $6990 HK $2142 HK $2509 HK $SNY $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
2
233
Each week, the five signals that matter most go to the BioSignal newsletter, with prompts for your AI agent. Free:
biosignal.beehiiv.com/?utm_s…
✨ Made with AI
🤖 Made with AI
59
China's CDE has proposed breakthrough therapy status for Lepu Biopharma's CDH17 ADC MRG007 in colorectal cancer after 2+ lines of systemic therapy (public notice 9 Nov).
The data behind it, from ESMO 2026: 6 mg/kg colorectal cohort, ORR 44.8% (13/29, of which 6 were unconfirmed or pending confirmation at cutoff), DCR 93.1%. Phase 1, company-reported.
Why it matters: ArriVent holds the rights outside Greater China, as ARR-217. Approved third-line colorectal drugs post single-digit response rates.
$2157 HK $AVBP $XBI $IBB
✨ Made with AI
🤖 Made with AI
219
JUST IN: China's 2026 commercial-insurance drug list adds three more CAR-Ts, including CARsgen's satri-cel, the first CAR-T approved for a solid tumour.
Per the NHSA list published today (effective 1 Jan 2027): 12 drugs added, 28 in total. New cell and gene therapy entries: satri-cel (CLDN18.2+/HER2- gastric or GEJ cancer after 2+ lines), Hrain's 雷尼基奥仑赛 (large B-cell lymphoma after 2+ lines), Chongqing Precision Bio's 普基奥仑赛 (CD19+ B-ALL, ages 3 to 21), and what NHSA calls China's first hemophilia gene therapy.
Why it matters: this list guides commercial insurers' coverage; the state fund does not pay for these drugs. Satri-cel's list price is RMB 990,000 per infusion (Caixin, June). Only one CAR-T made the state list this year.
$2171 HK $XBI $IBB
✨ Made with AI
🤖 Made with AI
4
353
RemeGen took most of its newest upfront in Vor Bio warrants.
Per both companies on 12 Nov, Vor adds RC298, a preclinical long-acting TACI-Fc fusion protein that blocks BAFF and APRIL, to its telitacicept licence, for rights outside Greater China. Upfront is about $56M: $10M cash plus pre-funded warrants for 2.3M Vor shares, valued at about $46M on the 11 Nov close. Up to $300M in development milestones; sales milestones and royalties follow the existing agreement. First China filing expected 1H 2027.
That stacks on the 2025 telitacicept deal: $45M cash plus a warrant for 16M Vor shares. RemeGen carried its Vor warrants at RMB 1.53B on 30 June.
Why it matters: more of RemeGen's reported profit now rides on Vor's share price.
$9995 HK $688331 SH $VOR $XBI $IBB
✨ Made with AI
🤖 Made with AI
152
China's state health insurance will pay for a CAR-T for the first time. One made the cut.
JW Therapeutics' relma-cel (Carteyva), a CD19 CAR-T, is on the 2026 basic reimbursement list NHSA published today, valid 1 Jan 2027 to end-2028. Coverage is restricted to adults with r/r large B-cell lymphoma after 2+ lines, r/r follicular lymphoma after 2+ lines, and r/r mantle cell lymphoma after 2+ lines including a BTK inhibitor. The price is confidential; NHSA says only that it was originally above RMB 1 million.
Most other approved CAR-Ts sit on the separate commercial-insurance list, including Fosun Kairos's axi-cel, CARsgen's zevor-cel and IASO's eque-cel. Legend/J&J's cilta-cel and Imunopharm's newly approved IM19 are on neither list. Relma-cel moved off the commercial list into the state scheme.
Relma-cel sold RMB 111.2M in H1 2026, 99.9% of JW's revenue. How much volume it gains at the new price is the number to watch.
$2126 HK $2196 HK $2171 HK $LEGN $JNJ $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
198
Each week, the five signals that matter most go to the BioSignal newsletter, with prompts for your AI agent. Free:
biosignal.beehiiv.com/?utm_s…
✨ Made with AI
🤖 Made with AI
57
Fosun Pharma's CAR-T unit has started a China Phase 2 of FKC516, an autologous CD20 CAR-T, in relapsed or refractory B-cell non-Hodgkin lymphoma.
Per Fosun's 12 Nov filing: the product was licensed in (the licensor isn't named), Fosun holds global rights in all indications, and it has spent about RMB 13.37M on it including licence fees. No data or trial size given. The filing says no CD20 CAR-T is approved in mainland China.
Why it matters: the unit is the former Fosun Kite, which sells Yescarta in China. Fosun bought out Kite's half in 2024 and renamed it; Kite keeps a royalty on the Kite products. FKC516 is the unit adding licensed assets beyond them.
$2196 HK $XBI $IBB
✨ Made with AI
🤖 Made with AI
1
174
